Manila Times Business
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Co
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bonoan rushed to hospital over ‘near stroke’ — Remulla
Just now
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics
Just now
BriaCell Presents Positive Clinical Data at ASCO 2026
Just now
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Just now